12% Convertible Debenture See Details Below
Unusual trading activity and a recent surge in price has called our attention to this canna-pharma company holding 4 US patents.
Revive Therapeutics – RVV TSX / RVVTF OTCQB : has a robust cannabis pharma focused patent portfolio, targeting multi-billion dollar disease markets, which includes exclusive rights to issued U.S. patents based on a unique drug delivery technology and the use of Cannabidiol for the potential treatment of a rare liver disease
These pharma shares are consolidating from a recent surge on high volume . We expect the recent advance to have a second leg testing again the $0.07 cent level then breaking out to the upside. With a new, highly experienced management team at the helm, we expect these shares to continue their advance and serious investors to place this company on their BUY LIST.
Revive Therapeutics to buy mushrooms from Red Light
Mr. Michael Frank reports
REVIVE THERAPEUTICS TO PURSUE THE PSYCHEDELIC MARKET WITH AGREEMENT AND INVESTMENT IN RED LIGHT HOLLAND FINANCING
Revive Therapeutics Ltd. has entered into a supply and collaboration agreement with Red Light Holland Financing Inc., an arm’s-length party.
Pursuant to the Agreement Red Light will sell to Revive a consistent strain of truffles for the sole purpose of Revive undertaking research and development on the suitability and implementation of its novel cannabinoid delivery technology with respect to the truffles and its extracts. Red Light has also agreed to, upon request, provide Revive with any information, studies, papers and other information it may have pertaining to the truffles which may be deemed to be beneficial to Revive for undertaking the research and development.
“Revive is excited to be working with Red Light to explore the use of its delivery technology with unique products such as truffles,” stated Michael Frank, the President of Revive. “We are confident that the results of Revive’s research will highlight the versatility of its cannabinoid delivery platform.”
“As Red Light Holland heads down the road of securing its facility in the Netherlands and commencing our cultivation of Premium Red Light Truffles, we are elated to be partnering and eventually aiming to supply companies with our truffles, such as Revive, who will perform true clinical testing in hopes of publishing ground-breaking and progressive medical results,” said Todd Shapiro, CEO of Red Light Holland.
In addition, as a condition of the Agreement, Revive has agreed to subscribe for 2,500,000 subscription receipts (the “Subscription Receipts”) of Red Light at a price of $0.06 per Subscription Receipt for an aggregate consideration of $150,000. Each Subscription Receipt shall entitle Revive, upon conversion and with any additional consideration, to acquire one common share in the capital of Red Light. In consideration for the Subscription Receipts, Revive will issue to Red Light an aggregate of 3,000,000 common shares in the capital of Revive at a price of $0.05 per share for aggregate consideration of $150,000.
About Revive Therapeutics Ltd.
Revive is a cannabis life sciences company focused on the research, development and commercialization of novel cannabinoid-based products. Revive’s novel cannabinoid delivery technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory and liver diseases. For more information, visit www.ReviveThera.com.
© 2020 Canjex Publishing Ltd. All rights reserved.
Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units
TORONTO, Feb. 05, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units (the “Debenture Units”) to arm’s length parties for aggregate gross proceeds of $210,000.
Each Debenture Unit consists of one (1) 12% secured convertible debenture (the “Convertible Debentures”) maturing three (3) years from the date of issuance and 20 common share purchase warrants of Revive (the “Warrants”). Each Warrant shall entitle the holder thereof to purchase one common share in the capital of Revive (each, a “Common Share”) at an exercise price of $0.07 at any time up to February 5, 2023.
The Convertible Debentures will have a maturity 36 months from the date of issuance (the “Maturity Date”) and shall bear interest at a rate of 12% per annum from the date of issue. Interest will accrue and be payable on the Maturity Date. The holder of the Convertible Debentures shall have the right to demand immediate payment of the Convertible Debentures, together will all accrued interest thereon, provided that such demand cannot be made prior to June 6, 2020.
The principal amount of each Convertible Debenture shall be convertible, for no additional consideration, into Common Shares at the option of the holder at any time prior to the close of business on the Maturity Date at a conversion price equal to $0.05 (the “Conversion Price”) per Common Share.
The proceeds from the issuance of the Convertible Debentures will be used for general working capital.
Chief Executive Officer
Revive Therapeutics Ltd.
Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
TORONTO, Jan. 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company’s announcement on January 6, 2020 regarding its clinical development plan on liver diseases, on the Company’s initiatives for its cannabinoid drug delivery program and its program of cannabidiol (“CBD”) in the prevention of ischemia and reperfusion injury (“IRI”) from organ transplantation.
“Revive is expanding its product pipeline by leveraging its FDA orphan drug designation for cannabidiol in the prevention of ischemia and reperfusion injury from organ transplantation,” said Michael Frank, Chief Executive Officer of Revive. “We are focused on building a unique cannabinoid-based product pipeline that focuses on rare inflammatory diseases including autoimmune liver diseases, IRI and inflammatory skin diseases and disorders. In addition to expanding our product pipeline, we are focused on partnering our product programs with cannabinoid-focused pharmaceutical companies, which we are currently in discussions with for both our cannabinoid delivery system and rare inflammatory disease programs.”
Revive’s novel drug delivery technology aims to deliver both synthetic cannabinoids and natural extracts of cannabis in a potential number of ways such as topical gels, creams or ointments, oral or transdermal patches, and oral dosages. The delivery technology is a natural, non-toxic, biodegradable and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has rapid onset of action and controlled or sustained release potential capabilities and may allow to combine multiple cannabinoids or cannabis extracts in one formulation. The Company seeks to develop novel drug products leveraging its drug delivery technology targeting multi-billion dollar market opportunities in pain, inflammatory skin disorders (i.e. acne, psoriasis), and wound healing applications (i.e. battle wounds, scarring).
In addition, Revive aims to develop a clinical development plan for CBD in the prevention of IRI from organ transplantation of the liver, kidney, heart and lung. The Company aims to have a pre-IND meeting with the U.S. Food and Drug Administration (“FDA”) to obtain feedback of Revive’s intended clinical development plan. The FDA granted the Company orphan drug designation for CBD in the prevention of IRI resulting from solid organ transplantation.
Revive’s program is to meet a clear unmet medical need in the prevention of IRI solid organ transplantation. According to the U.S. Organ Procurement and Transplantation Network, there are approximately 115,000 patients waiting for solid organ transplants in the United States, with the four most common organs transplanted being liver, kidney, heart and lung. IRI in organ transplantation can result in a higher incidence of acute and chronic rejection, as well as long-term morbidity and mortality. Quickly restoring blood supply of ischemic organs as soon as possible is crucial for avoiding or reducing injury from ischemia, whereas strategies used to attenuate the damage induced by reperfusion, including ischemic preconditioning, ischemic postconditioning, and machine perfusion. These strategies are expensive, sometimes hard to perform in clinical surgeries, and difficult in maintaining organ functions in the case of acute injuries. With the shortage of organs and expensive medical strategies, it is clear that therapies need to be researched to optimize the quality of the organs that are available and to attenuate injury to transplanted organs. Revive believes that the immunosuppressant and anti-inflammatory protective effects of CBD may provide a novel, more beneficial strategy to attenuate the damage induced by ischemia and reperfusion during solid organ transplantation.
ABOUT REVIVE THERAPEUTICS LTD.
Revive Therapeutics Ltd. is a cannabis life sciences company focused on the research, development and commercialization of novel cannabinoid-based products. The Company’s novel cannabinoid delivery technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory and liver diseases. For more information, visit www.ReviveThera.com.
Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases
TORONTO, Jan. 06, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’s clinical development plan for Autoimmune liver diseases, which includes Cannabidiol in the treatment of Autoimmune Hepatitis.
“Revive is leveraging its unique intellectual property portfolio and is focusing its efforts on building a pipeline of cannabinoid-based treatments for rare inflammatory diseases targeting multi-billion dollar markets,” said Michael Frank, Chief Executive Officer of Revive. “Our initial focus is advancing the clinical development of Cannabidiol in the treatment of Autoimmune Hepatitis towards a first-in-kind human clinical trial under a U.S. Investigational New Drug that will pave the way for pursuing our objectives in expanding our product pipeline of novel cannabinoid-based treatments for rare Autoimmune liver diseases and in bringing novel, targeted cannabinoid therapies to patients that need them most.”
Revive aims to build a portfolio of cannabinoid-based drugs for the treatment of rare inflammatory diseases with its initial focus on Autoimmune liver diseases (AILD). AILD are relatively rare diseases that are comprised of namely four indications including Autoimmune hepatitis (AIH), primary biliary cirrhosis, primary sclerosing cholangitis, and immunoglobulin G4 related cholangitis. These are chronic diseases that result in significant morbidity and mortality.
Revive will focus on the clinical development of Cannabidiol (CBD) in the treatment of AIH with plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 1H 2020 for a proposed Phase 1/2a clinical study to determine the recommended dose of CBD for future clinical studies, to assess its safety, efficacy and clinical benefit, as well as to support a New Drug Application (“NDA”). The Company aims to have a pre-IND meeting with the FDA to obtain feedback of Revive’s intended clinical development plan, including a proposed Phase 1/2a study design.
Revive’s program is to meet a clear unmet medical need in patients with AIH. AIH is a rare inflammatory condition of the liver that can affect all ages and gender across the world. If not treated properly, may cause liver fibrosis or cirrhosis, liver failure requiring a liver transplant, and even death. The prevalence of AIH is estimated at 75,000 patients in the U.S. The current standard of care for AIH is the use of steroids alone or steroids combined with azathioprine. It has been noted in medical literature that the current standard of care when used in a certain period of time has caused severe treatment-related side effects in 13%, treatment failure in 9%, incomplete response in 13%, and relapse after drug withdrawal up to 86% of patients with AIH (Source: World J Gastroenterol. 2010 Feb 28; 16(8): 934–947). Therefore, given the unwanted outcomes associated with a steroid-based therapy, an alternative steroid-free treatment option such as CBD, with its known safety profile, may provide a potential solution for an improved treatment strategy for those patients unresponsive to, intolerant of, or non-adherent with a steroid-based therapy for AIH.
Revive has an exclusive license from South Carolina Research Foundation for its intellectual property for the use of CBD, either in synthetic or natural form, in the treatment of autoimmune hepatitis (U.S. patent No. 8242178). Also, the FDA has granted to Revive orphan drug designation for CBD in the treatment of AIH, which provides valuable incentives that could accelerate the approval process, including seven-year market exclusivity, tax credits on U.S. clinical trials, fast-tracking of regulatory proceedings, and exemption from certain fees, such as waiver of filing fees under the Prescription Drug User Fee Act (PDUFA), and orphan drug grants.
Additionally, the Company will now not be proceeding with the subscription receipt private placement offering announced on November 12, 2019.
ABOUT REVIVE THERAPEUTICS LTD.
Revive Therapeutics Ltd. is a cannabis life sciences company focused on the research, development and commercialization of novel cannabinoid-based products. The Company’s novel cannabinoid delivery technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory and liver diseases.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that may cause actual results to differ materially from those anticipated by these forward looking statements include: uncertainties associated with the merger; uncertainties associated with reaching a definitive agreement to merge; uncertainties associated with obtaining regulatory approvals; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company’s ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and cannabis-centered companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in the Company’s Management’s Discussion & Analysis for the year ended June 30, 2019, the Company’s Annual Information Form for the year ended June 30, 2018, and continuous disclosure filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
|Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. Writer has been paid $650 / mo for writing and distributing this article The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.|